Last reviewed · How we verify
SC1011
At a glance
| Generic name | SC1011 |
|---|---|
| Also known as | Active Drug, experimental drug group |
| Sponsor | Guangzhou JOYO Pharma Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) (PHASE2, PHASE3)
- The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects. (PHASE1)
- Safety, Tolerability and Pharmacokinetic Study of SC1011 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SC1011 CI brief — competitive landscape report
- SC1011 updates RSS · CI watch RSS
- Guangzhou JOYO Pharma Co., Ltd portfolio CI